The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Publications

Izhakian S, Rosengarten D, Pertzov B, Grubstein A, Heching M, Fridel L, Kramer MR

Sertraline-Associated Interstitial Lung Disease: A case series and Literature Review.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG. 2021;38(3):e2021027

Lepore M, Campbell N

Sertraline as a rare cause of interstitial lung disease.

Oxford medical case reports. 2021;2021(4):omab014

Brancaleone P, Descamps O, Piquet M, Detry G, Mignon M, Weynand B

[Sertraline-induced chronic eosinophilic pneumonia].

Revue des maladies respiratoires. 2021;38(2):210-214

Virdee G, Bleasdale J, Ikramullah M, Graham-Clarke E

Sertraline-induced hypersensitivity pneumonitis.

BMJ case reports. 2019;12(12)

Müller NL, White DA, Jiang H, Gemma A

Diagnosis and management of drug-associated interstitial lung disease.

British journal of cancer. 2004;91 Suppl 2(Suppl 2):S24-30